8-K filed Aug 6, 2026 at 16:03 ET
Denali Therapeutics reported Q2 2026 results with AVLAYAH generating $3.6M in its first full commercial quarter, beating consensus revenue estimates of $2.2M. EPS of -$0.68 missed consensus of -$0.47 due to commercial build costs and lower interest income. Q3 AVLAYAH revenue guidance of $10-12M signals accelerating uptake, partially offsetting the negative pipeline news of the DNL151 (LRRK2) Phase 2b failure and the DNL593 (FTD-GRN) data delay to 2027.